Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. metabolism drug
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Metabolism Drug Articles & Analysis: Older

14 news found

CD Formulation Newly Launches Dissolving Microneedle Preparation Services: Enhancing Drug Delivery Efficiency   

CD Formulation Newly Launches Dissolving Microneedle Preparation Services: Enhancing Drug Delivery Efficiency  

CD Formulation, a leading provider of contract pharmaceutical formulation development services, recently announced the launch of its dissolving microneedle preparation services. This breakthrough in drug delivery technology promises to revolutionize the way medications are administered, enhancing efficiency and patient comfort. Microneedles are tiny, painless needles that penetrate the skin's ...

ByCD Formulation


Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Creative Enzymes, a global leader in enzyme production, is thrilled to announce the latest addition to their hydrolase product line, the Recombinant S-Adenosyl-L-Homocysteine Hydrolase (SAHH). This announcement underscores its unwavering commitment to enzyme innovation and proven track to offering scientifically advanced products. SAHH, a crucial enzyme involved in the biological methylation ...

ByCreative Enzymes


Araris Biotech appoints Bernd Schlereth as Chief Development Officer

Araris Biotech appoints Bernd Schlereth as Chief Development Officer

Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. Bernd Schlereth as Chief Development Officer (CDO). He brings with him more than 20 years of experience in pharmaceutical drug development. Between 2019 and 2021 Dr. Bernd Schlereth worked as Vice President Oncology Research at Molecular Partners AG. From 2013 to ...

ByAraris Biotech AG


Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. The company launches the drug-resistant metabolomics research service for oncology research and infectious disease studies regarding drug resistance. Drug therapy is one of the ...

ByCreative Proteomics


Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes

Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes

Optibrium and Lhasa Limited publish joint peer-reviewed research in the Journal of Medicinal Chemistry, expanding predictive modelling beyond human Cytochrome P450. Study demonstrates novel predictive models for drug metabolism to improve drug design and Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and ...

ByOptibrium Ltd.


CD Formulation Plays a Role in Developing Drug Delivery Systems

CD Formulation Plays a Role in Developing Drug Delivery Systems

Always at the forefront of innovation, CD Formulation continues to be a trustworthy CRO partner for pharmaceutical companies around the world. With unstopping efforts to expand its service portfolio, earlier this month, CD Formulation proudly announced the launch of drug delivery system development services, a move made not only to meet customers' drug development needs but also to exceed their ...

ByCD Formulation


Pronalyse Unveils Insightful Metabolite Identification Services of Biopharmaceuticals

Pronalyse Unveils Insightful Metabolite Identification Services of Biopharmaceuticals

Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development services. Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its metabolite identification services of biopharmaceuticals for an accurate and efficient analysis of the metabolism for your biological drugs in vivo. The ...

ByCreative Proteomics


Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery

Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery

Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative ...

ByIktos


Alfa Chemistry Now Offers Pharmaceutical and Drug Standards for Drug Discovery

Alfa Chemistry Now Offers Pharmaceutical and Drug Standards for Drug Discovery

Uniquely positioned to be a dedicated player in the analytical testing industry, Alfa Chemistry supplies a full range of analytical reagents. Today it announces to add pharmaceutical and drug standards to its already rich offering of chromatography standards. After this move, researchers can now easily have access to certified reference materials, environmental standards, food & beverage ...

ByAlfa Chemistry


Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range

Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range

Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS) The companies share a common goal of developing and supplying advanced cell models that better reflect an in vivo environment to improve drug discovery accuracy ...

ByLonza Group Ltd


Microvi and Nexilico Develop Powerful Computational Platform for Gut Microbiome funded by NIH

Microvi and Nexilico Develop Powerful Computational Platform for Gut Microbiome funded by NIH

Under a National Institute of Health (NIH) grant awarded by the National Institute of General Medical Sciences (NIGMS), Microvi, Nexilico, and their research partners have developed a first-of-its-kind predictive computational platform focused on the gut microbiome and its interaction with therapeutics. The in silico platform reduces the cost and timeframe of drug development by reducing the ...

ByMIcrovi Biotech, Inc.


Wired: This startup wants to stop deaths from cardiac arrest?

Wired: This startup wants to stop deaths from cardiac arrest?

In April 2013, final-year Danish medical student Habib Frost was called out to an emergency: a four-month old girl had just suffered cardiac arrest. Frost’s team tried defibrillation, but to no avail. Immediately after, the team was called out again: another case of cardiac arrest, this time a woman in her 30s. Once again, Frost was powerless to save her life. “I felt ...

ByNeurescue


UA College of Pharmacy researchers link liver disease and drug metabolism

Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes. People develop NASH when early liver disease, characterized by too much fat in the liver, is exacerbated by inflammation. Obesity, which is on ...

ByNational Institute of Environmental Health Sciences (NIEHS)


Studies Show Genetic Variations in Multiple Chemical Sensitivity

Studies Show Genetic Variations in Multiple Chemical Sensitivity

Salem, NY -- Three recent studies show that a genetic variant makes sufferers of multiple chemical sensitivity (MCS) more likely to develop the condition. In 2004, McKeown-Eyssen studied 203 MCS sufferers and 162 controls and found that genetic differences relating to detoxification processes were present more often in those with MCS than those without. The study concluded that 'a genetic ...

ByMCS America

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT